



Glaucoma.
We've got it surrounded.

GLAUCOMA
360°

— NEW
— HORIZONS
— FORUM

February 3, 2012

The Palace Hotel | San Francisco, CA

Presented by

GLAUCOMA
RESEARCH FOUNDATION

In Association with

Ophthalmology Times

ADVISORY BOARD

GLAUCOMA
360°



Stuart B. Abelson, MBA

*President, Chief Executive Officer
Ora, Inc.
Andover, MA*



Wende Hutton

*General Partner
Canaan Partners
Menlo Park, CA*



William J. Link, PhD

*Managing Director
Versant Ventures
Newport Beach, CA*



Anthony P. Adamis, MD

*VP & Global Head of Ophthalmology
Genentech, Inc.
San Francisco, CA*



Ralf Kuschmeyer, PhD

*President & CEO
Carl Zeiss Meditec, Inc.
Dublin, CA*



Sabri Markabi, MD

*Sr. VP, R&D and CMO
Alcon Laboratories, Inc.
Fort Worth, TX*



Paul Chaney

*President & CEO
PanOptica, Inc.
Bernardsville, NJ*



Eliot Lazar, MD

*President
ELCON Medical
Buffalo, NY*



James Mazzo

*President and CEO
Abbott Medical Optics
Santa Ana, CA*



George A. Cioffi, MD

*Chairman
Devers Eye Institute
Portland, OR*



Richard Lindstrom, MD

*Founder
Minnesota Eye Consultants, PA
Minneapolis, MN*



David Mordaunt, PhD

*VP, Research and
Development - Surgical
Bausch + Lomb
Madison, NJ*



Alan Crandall, MD

*John A. Moran Eye Center
University of Utah
Salt Lake City, UT*



John W. Grunden, PharmD

*Regional Director of Medical Affairs
Merck & Co., Inc.
Whitehouse Station, NJ*



Gary D. Novack, PhD

*President
PharmaLogic Development, Inc.
San Rafael, CA*



Emmett Cunningham, Jr., MD, PhD, MPH

*Partner
Clarus Ventures
San Francisco, CA*



David Guyer, MD

*Partner
SV Life Sciences Advisers, LLC
Boston, MA*



David E.I. Pyott

*Chairman of the Board,
President & CEO
Allergan, Inc.
Irvine, CA*



Eugene de Juan, Jr., MD

*Founder & Vice-Chairman
ForSight Labs
San Francisco, CA*



H. Dunbar Hoskins, Jr., MD

*Former Executive Vice President
American Academy
of Ophthalmology
San Francisco, CA*



Ellen Strahlman, MD, MHSc

*Chief Medical Officer
GlaxoSmithKline
Philadelphia, PA*

WELCOME



Adrienne Graves, PhD

*Former President & CEO, Santen Inc.
Board of Directors,
Glaucoma Research Foundation
San Francisco, CA*



Andrew G. Iwach, MD

*Executive Director
Glaucoma Center of San Francisco
San Francisco, CA*

Collaborating for **breakthrough therapy**

Welcome everyone. On behalf of Glaucoma Research Foundation, welcome to Glaucoma 360: New Horizons Forum, a genuinely historic day in our shared vision of a world mobilizing to beat the global epidemic of blindness presented by glaucoma. This is the first conference of this type in the United States focusing solely on showcasing the promise of innovative new ideas that bring genuine hope for better treatments and ultimately a cure for glaucoma.

We are most excited, not only that you are here with us to inaugurate this auspicious moment, but that all proceeds from all Glaucoma 360 events directly benefit Glaucoma Research Foundation grant-making and patient education.

OUR GOALS TODAY ARE TWOFOLD:

- To significantly boost national awareness of the threat of blindness from glaucoma to aging and high-risk populations and to demonstrate that all of us working together — those affected, caregivers, researchers, funders, families and friends — develop more ways to stop this silent thief of sight. In short: beating glaucoma needs to be a national health priority and a personal health concern for each of us.

- To bring together nationally and internationally respected leaders in medicine, science, business, venture capital, philanthropy, and media to share collaboratively our best thinking. In the process, we will catalyze ever more effective therapies and accelerate the pace of discovery. Your presence here today galvanizes us all with your extraordinary breakthroughs, inspires us with your dynamic leadership, and reminds us of the great compassion at the heart of all our efforts.

Today could not be possible without the generous and selfless contributions of so many: members of our Advisory Board who have all been so actively involved with our planning; our sponsors, without whom we simply couldn't have this opportunity to bring us all together; our speakers, presenters and panelists ready to share their expertise and perspectives; our registrants; the talented staff of our marketing partner *Ophthalmology Times*; the resourceful board and staff at Glaucoma Research Foundation; and the helpful team at The Palace Hotel.

Thank you.

Adrienne Graves, PhD
Co-Founder, Co-Chair
New Horizons Forum

Andrew Iwach, MD
Co-Founder, Co-Chair
New Horizons Forum

PLATINUM SPONSORS



SILVER SPONSORS



BRONZE SPONSORS

- | | |
|------------------------------|----------------------------|
| Accutome, Inc. | iCo Therapeutics, Inc. |
| Aerie Pharmaceuticals, Inc. | iScience Interventional |
| Altheos, Inc. | Isis Pharmaceuticals, Inc. |
| Glaukos Corporation | PPD Inc |
| Heidelberg Engineering, Inc. | Transcend Medical, Inc. |

COPPER SPONSORS

- | | |
|-----------------------------------|----------------------|
| Alloy Ventures | NeoMedix Corporation |
| Amorphex Therapeutics, LLC. | PanOptica, Inc. |
| Dow Pharmaceutical Sciences, Inc. | QLT, Inc. |
| IOP Ophthalmics | TearLab Corporation |
| Iridex Corporation | |



Thomas M. Brunner

*President and CEO
Glaucoma Research Foundation
San Francisco, CA*

Speeding the cure. Spreading the word.

Welcome. On behalf of our Board of Directors, staff, collaborative researchers, funders and volunteers at Glaucoma Research Foundation, thank you for coming to Glaucoma 360: New Horizons Forum and making possible this extraordinary day!

We have a rallying cry here at Glaucoma Research Foundation that drives us forward: “Speeding the cure. Spreading the word.” It is this call to action that has stimulated us to design and launch Glaucoma 360: a three-day series of events making possible an extraordinary full-compass view of The Cure, The Catalysts and The Care in glaucoma today.

Glaucoma 360 officially began last night with our annual benefit, “Catalyst For a Cure,” where we focused on raising the funds that make possible continuing research and patient education. The “New Horizons Forum” today focuses on the kind of new ideas that can bring relief in the very near term to those we serve. And then Saturday, we feel very proud to offer “Glaucoma Symposium CME” in partnership with the Glaucoma Research and Education Group, focusing on latest treatments and therapies for practicing ophthalmologists.

The mission of Glaucoma Research Foundation is: preventing vision loss from glaucoma by investing in innovative research, education and support with the ultimate goal of finding a cure. Your presence here today serves that mission generously and makes possible at least two priceless gifts for Glaucoma Research Foundation and, in turn, those families and friends affected by glaucoma whom we are able to serve. First, all proceeds from all Glaucoma 360 events benefit Glaucoma Research Foundation and provide funds to continue the kind of innovative research initiatives that our Scientific Advisory Board feels will accelerate the pace of discovery. Second, the visionary brand of results-oriented creative thinking you all bring, when shared in the collaborative spirit that is a core value for Glaucoma Research Foundation, graphically demonstrates that there is every reason for great hope we will beat glaucoma.

Thank you for making this possible.

Sincerely,
Thomas M. Brunner
President and CEO

7:00 - 7:30	Breakfast and Exhibits
7:30 - 7:40	<p>Welcome</p> <p>Adrienne Graves, PhD, Glaucoma 360 Founder and Co-Chair, Board of Directors, Glaucoma Research Foundation and Former President and CEO, Santen Inc.</p> <p>Andrew G. Iwach, MD, Glaucoma 360 Founder and Co-Chair, Executive Director, Glaucoma Center of San Francisco</p>
7:40 - 8:00	<p>State of Glaucoma Therapy: 2012</p> <p>George A. Cioffi, MD, Chairman, Devers Eye Institute</p>
8:00 - 9:30	<p>New Horizons in Glaucoma Devices</p> <p>8:00-8:05 Moderator: Alan Crandall, MD, John A. Moran Eye Center</p> <p>8:05-8:14 Glaukos Corporation David Applegate, VP Marketing and Business Development</p> <p>8:14-8:23 Transcend Medical, Inc. Brian Walsh, President and CEO</p> <p>8:23-8:32 iScience Interventional Michael F. Nash, President, CEO and Director</p> <p>8:32-8:43 NeoMedix Corporation Soheila Mirhashemi, PhD, CEO</p> <p>8:43-8:52 Optovue, Inc. Jay Wei, Founder and President/CEO</p> <p>8:52-9:01 Compact Imaging, Inc. Don Bogue, CEO</p> <p>9:01-9:30 Audience Q&A</p>
9:30 - 10:00	Break, Exhibits and Networking
10:00 - 11:00	<p>New Horizons in Glaucoma Drug Delivery and IOP Monitoring</p> <p>10:00-10:05 Moderator: Eliot Lazar, MD, President, ELCON Medical</p> <p>10:05-10:14 Amorphex Therapeutics, LLC Robert F. Thompson, Chairman and CEO</p> <p>10:14-10:23 pSivida Corp. Paul Ashton, PhD, President and CEO</p> <p>10:23-10:32 AcuMEMS, Inc. Douglas Lee, President and CEO</p> <p>10:32-10:41 Implants Ophthalmic Products GmbH Max G. Ostermeier, MBA, CEO</p> <p>10:41-11:00 Audience Q&A</p>
11:00 - 11:45	<p>Venture Capital Panel Discussion</p> <p>Moderator: Emmett Cunningham, Jr., MD, PhD, MPH, Partner, Clarus Ventures</p> <p>Panelists: William J. Link, PhD, Managing Director, Versant Ventures Wende Hutton, General Partner, Canaan Partners Eugene de Juan, Jr., MD, Founder and Vice-Chairman, ForSight Labs Anand Mehra, MD, Partner, Sofinnova Ventures</p>
11:45 - 12:45	Luncheon, Exhibits and Networking
12:45 - 1:20	<p>Interview: Getting There from Go</p> <p>H. Dunbar Hoskins, Jr., MD, former EVP American Academy of Ophthalmology and Co-Founder, Glaucoma Research Foundation</p> <p>James Mazzo, President and CEO, Abbott Medical Optics</p>

- 1:20 - 2:15 New Horizons in Glaucoma Pharmaceuticals**
- 1:20-1:25 Co-moderators: Anthony P. Adamis, MD**, VP and Global Head of Ophthalmology, Genentech, Inc. and **Paul Chaney**, President and CEO, PanOptica, Inc.
- 1:25-1:34 Aerie Pharmaceuticals, Inc. Thomas J. van Haarlem, MD**, President and CEO
- 1:34-1:43 Altheos, Inc. Henry Hsu, MD**, CEO
- 1:43-1:52 Amakem NV Jack Elands, PhD**, CEO
- 1:52-2:01 Isis Pharmaceuticals, Inc. Scott Henry, PhD, DABT**, VP Non-Clinical Development
- 2:01-2:15 Audience Q&A**
-
- 2:15 - 3:00 Pharmaceutical Industry Panel**
Moderator: Stuart B. Abelson, MBA, President and CEO, ORA, Inc.
Panelists: Alcon Laboratories, Inc., Iok-Hou Pang, PhD, Head Glaucoma Research
Allergan, Inc., Rhett M. Schiffman, MD, MS, MHSA, VP and Therapeutic Area Head, Ophthalmology
Merck & Co., Inc., John W. Grunden, PharmD, Regional Director of Medical Affairs
Genentech, Inc., Anthony P. Adamis, MD, VP and Global Head of Ophthalmology
-
- 3:00 - 3:30 Break, Exhibits, and Networking**
-
- 3:30 - 3:45 Towards the Use of Metabolic Biomarkers in Glaucoma Diagnosis and Management**
Martin B. Wax, MD, Chief Medical Officer and EVP R&D, PanOptica, Inc.
-
- 3:45 - 4:30 Device Industry Panel**
Moderator: Richard Lindstrom, MD, Founder, Minnesota Eye Consultants, PA
Panelists: Abbott Medical Optics, Jane Rady, Divisional VP, Business Development
Bausch + Lomb, Dave Mordaunt, PhD, VP Research & Development - Surgical
Carl Zeiss Meditec, Inc., Mike Patella, VP Professional Affairs
Lumenis Ltd., Kfir Azoulay, VP and GM, Ophthalmology Business Unit
-
- 4:30 - 5:25 New Horizons at the FDA**
4:30 - 4:35 Co-moderators: Gary D. Novack, PhD, President, PharmaLogic Development, Inc. and **Ellen Strahlman, MD, MHSc**, Chief Medical Officer, GlaxoSmithKline
- 4:35 - 4:55 The Glaucoma Drug Approval Process: What You Need to Know**
Wiley A. Chambers, MD, Deputy Director of the Division of Transplant and Ophthalmology Products in the Center for Drug Evaluation and Research, Food and Drug Administration
- 4:55 - 5:15 Glaucoma Devices: The Fastest Way to U.S. Market**
Malvina B. Eydelman, MD, Division Director, Division of Ophthalmic, Neurological & Ear Nose and Throat Devices, Food and Drug Administration
- 5:15 - 5:25 Audience Q&A**
-
- 5:25 - 5:30 Closing Remarks**
Adrienne Graves, PhD
Andrew G. Iwach, MD
-
- 5:30 - 7:00 Reception, Exhibits and Networking**

Glaucoma 360 Co-Founders & Co-Chairs



Adrienne Graves, PhD, Former President and Chief Executive Officer, Santen Inc.,
Board of Directors, Glaucoma Research Foundation

Dr. Graves is a visual scientist by training and a global industry leader in ophthalmology. As the former CEO of Santen Inc., the US subsidiary of Japan's leading ophthalmic pharmaceutical company, she successfully established a strong US presence by bringing multiple ophthalmic products through development to approval and commercialization.

Dr. Graves led global teams at Santen through successful acquisitions and partnerships. Prior to her 15 years at Santen, Dr.

Graves spent 9 years at Alcon, where she won the Technical Excellence Award and served as Director of International Ophthalmology.

She is a dynamic, highly sought-after international speaker on topics of leadership development, scientific careers, women's leadership/mentoring, and scientific and business development.

Dr. Graves serves on the boards of TearLab Corporation, Encore Vision, Inc., American Society of Cataract and Refractive Surgery

Foundation, Glaucoma Research Foundation, American Academy of Ophthalmology Foundation (Emeritus), Pan-American Ophthalmology Foundation, KeepYourSight Foundation, Brown University Medical School, and the Advisory Board for Amach Capital Partners.

She received her Ph.D. in Psychobiology from the University of Michigan, Ann Arbor and did her Postdoctoral Fellowship in Visual Neuroscience at the University of Paris, France. She received her AB with Honors in Psychology from Brown University in Providence, RI.



Andrew G. Iwach, MD, Executive Director, Glaucoma Center of San Francisco; Executive Director,
Glaucoma Research and Education Group; Chair, Board of Directors, Glaucoma Research Foundation

Dr. Iwach has been a member on the board of directors for the Glaucoma Research Foundation since 2000 and is currently serving as its Chair. He was appointed Chair of the Department of Ophthalmology at St. Mary's Hospital and Medical Center in 1999 and has served as Vice Chair since 2002.

He currently serves as a scientific reviewer for *Ophthalmology*, *American Journal of Ophthalmology*, *Archives of Ophthalmology*, *Ophthalmic Surgery and Lasers* and the *Journal of Glaucoma*. Since becoming a fellow of the Academy in 1991, he has been active in many facets of the AAO organization, including

volunteering with EyeCare America, being a member on the Medical Information Technology and the Computer-Based Patient Records Activities committees and serving as a media spokesperson. In 1994, Dr. Iwach received the Academy's Honor Award and in 2004 he received the Senior Achievement Award.

He is an associate clinical professor of ophthalmology in the department of ophthalmology at the University of California, San Francisco. He is on the clinical faculty at California Pacific Medical Center. He teaches courses and lectures extensively on glaucoma, having presented more than 300 scientific

lectures both nationally and internationally. Dr. Iwach is actively involved in clinical research, as well. His research focus has included mitomycin-C use in filtering surgery, application of optical coherence tomography in glaucoma, selective laser trabeculoplasty, numerous drug trials and more. He has published more than 40 peer-reviewed papers and book chapters.

Dr. Iwach received his medical degree from the University of California Los Angeles and did his ophthalmology residency at Stanford University. He completed a Shaffer glaucoma fellowship at the University of California San Francisco in 1989.



Thomas M. Brunner, President and Chief Executive Officer,
Glaucoma Research Foundation

Mr. Brunner joined Glaucoma Research Foundation in 2003 after a successful 30 year career in the ophthalmic laser business. He helped introduce major advances in eye care including laser photocoagulation to prevent vision loss from diabetic retinopathy, laser treatment of secondary cataracts, and laser treatment for glaucoma.

He received a "Lifetime Achievement" award from the American Society for Laser Medicine and Surgery for his contributions and 25 years of service on their Board of Directors. He serves on the Board of Directors for Abilities United, a non-profit serving those with developmental disabilities, and the San Francisco Rotary Club. In addition, Tom

actively supports innovative new products to help those with glaucoma and other eye diseases as an advisor or board member for startup companies in the eye care field. Tom graduated from Lehigh with a degree in electrical engineering and received an MBA from the University of Delaware.



DAVID APPLGATE, Vice President, Marketing and Business Development, Glaukos Corporation

has over 25 years of medical device general management, marketing and sales experience in several specialties including ophthalmology, optometry, otolaryngology, spine and cosmetic surgery. He has specific expertise in the launch and commercialization of medical devices including 1-DAY ACUVUE® Daily Disposable Contact Lenses and the Summit SVS Apex Excimer Laser System. Mr. Applegate has been with Glaukos Corporation since 2009.



PAUL ASHTON, PhD, President and Chief Executive Officer, pSivida Corp.

was named the Company's President & Chief Executive Officer in January 2009 after having previously served as Managing Director from January 2007 to January 2009 and Executive Director of Strategy from December 2005 to January 2007. Dr. Ashton was the President and Chief Executive Officer of Control Delivery Systems, Inc. from 1996 until its acquisition by pSivida in December 2005. CDS was a drug delivery company that Dr. Ashton co-founded in 1991. Prior to co-founding CDS, Dr. Ashton was a joint faculty member in the Departments of Ophthalmology and Surgery at the University of Kentucky, served on the faculty of Tufts University and worked as a pharmaceutical scientist at Hoffman-La-Roche. Dr. Ashton received a Bachelor of Science degree in chemistry from Durham University, England, and a Ph.D. in pharmaceutical science from the University of Wales.



DON BOGUE, Chief Executive Officer, Compact Imaging, Inc.,

is a veteran Silicon Valley executive and entrepreneur, joining Compact Imaging, Inc. (CI) as CEO in December 2010. CI is an early stage optical technology company focused on the expanding market for non-invasive imaging and measurement devices. Don came to CI after leading the successful licensing and sale of the intellectual property assets of Command Audio, a company he co-founded

in 1995 and led from its inception. Command Audio held fundamental patents for on-demand media applications such as digital video recorders (DVRs), advanced digital radios and associated services. Under Don's leadership, the privately-held company created and launched to consumers an entirely new information and entertainment device and service, raised over \$85 million from venture investors and strategic partners, enforced its intellectual property and licensed its technology to major media and manufacturing companies, including Cisco/Scientific Atlanta, Motorola, Sirius Satellite Radio, Sony and Thomson Consumer Electronics. Prior to Command Audio, Don held senior leadership positions with Gigatronics, Inc. and Ampex Corporation. Don has a degree in economics from Harvard University.



JACK ELANDS, PhD, Chief Executive Officer, Amakem NV

has been the CEO of Amakem since its inception in 2010. Previous to his role as CEO at Amakem, Dr. Elands served as the CBO of Silicos, an informatics platform based biotechnology company. Prior to that, Dr. Elands served as the CEO of Vitec, a specialty biochemical company focused on antimicrobial surface chemistries and products and the VP of Business Development at Sidec AB, a Swedish company focused on the discovery and development of protein based drugs. Dr. Elands started his pharmaceutical career at Marion Merrell Dow (later HMR, now Sanofi-Aventis). He has published extensively in papers and posters on topics ranging from biomolecular screening to protein tomography to life science informatics and functional genomics and has contributed to several patents. He received his undergraduate in medical biology from University of Utrecht in 1985. Jack was awarded his doctorate in Neuropharmacology from the Rudolf Magnus Institute at University of Utrecht in 1989.



SCOTT HENRY, PhD, DABT, Vice President of Non-Clinical Development, Isis Pharmaceuticals, Inc.,

received a Ph.D. in Biochemistry from North Dakota State University in

1991, studying the phosphorylation and regulation of the glycogen synthesis pathway in heart. Following his Ph.D., he was a post-doctoral fellow at Parke Davis in Ann Arbor Michigan in the department of toxicology until 1993. He then joined Isis Pharmaceuticals, Inc. as a Senior Scientist in the department of toxicology. Along with a team of dedicated colleagues, he has characterized and studied the mechanisms of various toxicities that include the effects of oligonucleotide treatment on clotting time prolongation, alternative complement pathway activation, proinflammatory effects in rodents, and the effects related to the accumulation of oligonucleotide in kidney. Now as Vice President of Non-Clinical Development at Isis he has participated in the development of approximately 8 different phosphorothioate oligodeoxynucleotides and 18 different 2'-MOE modified phosphorothioate oligonucleotides.



HENRY H. HSU, MD, Chief Executive Officer, Altheos, Inc., is a co-founder of Altheos and a Director on the company's Board. Dr. Hsu has extensive experience leading drug development programs, from translational research and pre-clinical

development, through all phases of clinical development, and post-marketing medical affairs. From 2005 to 2009, Dr. Hsu served as Chief Medical Officer of CoMentis, a privately-held biopharmaceutical company focused on neurologic and ophthalmic diseases. Previously, Dr. Hsu was Vice President, Clinical Research, at CoTherix, where he led the clinical team in the approval in the US of inhaled iloprost (Ventavis®) for the treatment of pulmonary arterial hypertension. Prior to CoTherix, he was Vice President, Clinical Research at InterMune, where he was responsible for clinical development and medical affairs for a number of products. From 1995 to 1999, Dr. Hsu served in various senior positions at Chiron Corporation, within both the vaccines and biopharmaceutical divisions. Dr. Hsu received an M.D. from the University of California, San Francisco, School of Medicine, and a B.S. in biology from Johns Hopkins University. He was a recipient of a postdoctoral fellowship from the Howard Hughes Medical Institute and conducted basic research in molecular virology at Stanford University Medical Center.



DOUGLAS LEE, President and Chief Executive Officer, AcuMEMS, Inc.,

has been CEO of OrthoMEMS and its subsidiary AcuMEMS since its inception in 2004. Previously, Mr. Lee was CEO of The Dr. Spock Company, a venture-backed company in children's health from 2000 to 2003. Prior to that, Mr. Lee was Managing Director of Premier Medical Partner Fund LP, a healthcare venture capital fund from 1997 to 2001. Before Premier, he was CFO and Vice President of the new ventures and corporate business development group at Guidant Corporation from 1995 to 1997. Earlier in his career, Mr. Lee was an investment banker at Montgomery Securities, Goldman Sachs and Kemper Securities. Mr. Lee has served as a board member or observer of several successful venture-backed medical technology companies, including Atrionix (sold to Johnson & Johnson), Durect Corporation (NASDAQ: DRRX), and Endotex Interventional Systems (acquired by Boston Scientific). Mr. Lee earned a B.S. in business administration from the University of California at Berkeley in 1987 and an MBA from the University of Chicago in 1991.

SOHEILA MIRHASHEMI, PhD, Co-Founder and Chief Executive Officer, NeoMedix Corporation,

developed Trabectome for Minimally Invasive Glaucoma Surgery for infantile and adult glaucomas. Dr. Mirhashemi earned her Ph.D. in Biomedical Engineering from the University of California, San Diego in 1986, developing a mathematical model of micro and macro circulations which led to a Principal Engineer position at Edwards Life Sciences and then Baxter. Then with two colleagues and based on her MBA dissertation, she founded NeoMedix Corporation. Additionally, her dissertation won a Small Business Innovation Research Grant from the National Eye Institute of National Institute of Health for Minimally Invasive Cataract Surgery, and resulting work was then subsequently sold to Bausch + Lomb. In 2003, Soheila's mother was diagnosed with glaucoma and was referred to Dr. Baerveldt, which led to the development of Trabectome for Minimally Invasive Glaucoma Surgery that became commercialized as Trabectome in the US in 2006. Currently, Trabectome has received regulatory approval

from the US, Japan, Europe, China, the Middle-East, and a majority of Asian countries. Dr. Mirhashemi is looking forward to providing easy and affordable access to Trabectome as a minimally invasive glaucoma treatment through various scientific and non-profit organizations such as glaucoma foundations as well as commercial efforts.



MICHAEL F. NASH, President, Chief Executive Officer and Director, iScience Interventional, is an experienced medical business executive and analyst with a strong background in ophthalmic products and services. Mr.

Nash's business experience includes senior management responsibilities at General Surgical Innovations Inc., Ioptex Research Inc., Oculex Pharmaceuticals Inc., Orthopedic Technology Inc. as well as direct project management of new medical products from concept through commercialization at Ioptex Research, Inc. and American Medical Optics, Division of American Hospital Supply. Mr. Nash has a strong background in market research, market development, and business development. Mr. Nash received a BA degree in economics from the University of Michigan and a MBA degree in strategic marketing from Pepperdine University.



MAX G. OSTERMEIER, MBA, Founder and Chief Executive Officer, Implants Ophthalmic Products GmbH, has extensive experience in the commercial development of technologically advanced products, in

building operational capabilities for aggressively growing companies and in creating businesses, attracting potential acquirers in the global market. As serial entrepreneur he was founder and CEO of Odicrain GmbH, Germany, developer of a new to the world portable device for rapid detection of intracranial bleeding, which was acquired by Optical Diagnostic Systems, LLC, in 2007. Mr. Ostermeier was also co-founder and CEO of Cranium Telemetry GmbH, a company with innovative neurosurgical products which was acquired 4 years after founding by a leading US medical device

company. Prior to that he was instrumental in creating for Degussa, a globally leading fine chemistry company their biotech entity Proligo LLC, Boulder, CO, where he served as General Manager and Vice President until this company was divested to Sigma Aldrich. His MBA background and his passion for M&S allows him to understand and efficiently develop products addressing a high unmet need, offering significant market potentials.



ROBERT F. THOMPSON, Chairman and Chief Executive Officer, Amorphex Therapeutics, LLC.,

a sustained ophthalmic drug delivery technology company, has over 25 years of sales, marketing and executive experience

in medical device and OTC consumer markets. He has been a senior executive with early stage companies with devices including a breast cancer MRI scanner, a hand held instrument for the detection of pediatric middle ear fluid, a device for measuring blood perfusion, and fertility diagnostic products. He has also acted as an intermediary in the sale/divestiture of several ophthalmic product lines. He was formerly a corporate officer of Bausch + Lomb and president of Polymer Technology Corporation. Bob joined Polymer Technology in its early, venture capital financed stage prior to acquisition by Bausch + Lomb and held various senior sales and marketing positions with the company during its sustained growth to become the world's leading provider of gas permeable contact lens products. Bob is a graduate of Boston University's School of Management and of Harvard Business School's Program for Management Development.

Funding innovative research to find a **cure for glaucoma**

Founded in 1978 in San Francisco, the Glaucoma Research Foundation (GRF) was created to encourage innovative research to find better ways to care for people with glaucoma, and ultimately find a cure.

Over 2.2 million Americans and 60 million worldwide have glaucoma. More than 120,000 Americans are blind from glaucoma. Glaucoma is the leading cause of blindness in African Americans and the second leading cause of blindness worldwide after cataracts.

RESEARCH

Successful research grants funded by Glaucoma Research Foundation include the Collaborative Normal Tension Glaucoma Study, the first controlled clinical trial to establish that lowering eye pressure preserves vision. Another GRF grant funded one of the first research studies to identify a gene that causes glaucoma.

A major collaborative study, now in its 10th year, Catalyst For a Cure (CFC), is redefining glaucoma research and how it is conducted. The CFC research scientists — specialists in genetics, nerve regeneration, and neurodevelopment — work in real-time collaboration to understand neuronal loss in glaucoma and identify targets for intervention.



GRF founders in 1989 (L-R) Robert Shaffer, MD, H. Dunbar Hoskins, Jr., MD, and John Hetherington, MD.

This research is made possible almost entirely by individual private donors. GRF receives no government funding and 84% of all funds raised go to funding research and education.

In 2012, GRF is launching “Glaucoma 360” to bring together donors, doctors, researchers, industry, and investors in a 3-day series of events, including: The GRF Annual Benefit, The New Horizons Forum, and the Glaucoma Symposium CME. The goal is to accelerate glaucoma research and development, share advancements in research, treatments and therapies, and foster better ways to care for people with glaucoma.

EDUCATION

The GRF website, www.glaucoma.org, has a wide range of information and news for glaucoma patients and their families. With a million visitors a year, it is a top Internet search choice for “glaucoma” and a model of accessibility for the vision impaired.

GRF’s free newsletter, *Gleams*, with a circulation of 90,000, offers the latest information about glaucoma treatments and research. GRF publishes and distributes free patient education materials including a comprehensive 32-page booklet “Understanding and Living with Glaucoma.”



THOMAS J. VAN HAARLEM, MD, President and Chief Executive Officer, Aerie Pharmaceuticals, Inc., started the company in 2005.

He established and expanded the company's research and development operations in state-of-the-art laboratories in Research Triangle Park, North Carolina. In 2007, he added an Aerie corporate office in Bridgewater, New Jersey. Aerie has raised \$61 million since its inception to successfully discover and develop its portfolio of novel proprietary ophthalmic drugs. Dr. van Haarlem has broad leadership experience based on twenty years in commercial, strategic and development positions at Pfizer, Pharmacia and Merck, both in the U.S. and in Europe. Dr. van Haarlem earned an MD degree from the University of Amsterdam and completed his business education at the NIMA Institute in the Netherlands.



BRIAN WALSH, President and Chief Executive Officer, Transcend Medical Inc., has more than twenty

years of experience in the medical industry, working with high-growth companies throughout his career to offer significant advancements to physicians and patients. Mr. Walsh is the President & CEO of Transcend Medical, Inc., a medical device company focused on replacing the current therapies for the treatment of glaucoma with a less invasive procedure and minimal complications. Prior to joining Transcend Medical almost 5 years ago, Mr. Walsh held several senior level positions with medical device companies: Vice President of Sales and Marketing of Xtent, Inc., Vice President of Sales and Marketing of Ventricle and Director of Sales for Artemis Medical, Inc. He also worked as a consultant with the CardioVations Division of Ethicon, a Johnson & Johnson Company. Previously, Mr. Walsh held a variety of sales and sales training positions at Guidant, Devices for Vascular Intervention and Marion Merrell Dow. Mr. Walsh holds a B.S. in Marketing from St. Joseph's University.



JAY WEI, Founder and President/Chief Executive Officer, Optovue, Inc., has over 19 years product development and management experience

in the medical device industry. He was fortunate to see the birth of OCT technology and subsequently pioneered the commercialization of the optical coherence technology for ophthalmic diagnosis since 1994. Jay founded Optovue in 2004 to develop the next generation of Ophthalmic OCT instruments. His vision of the clinical use of OCT technology has resulted in the first FDA cleared Fourier-domain OCT system, the RTVue®. As president of Optovue, he continues to direct company efforts towards making OCT available to every eyecare professional and patient. Optovue first built the RTVue as a multipurpose platform making it more cost effective. 2009 saw the introduction of iVue®, a compact, easy to use device at a lower cost. iWellnessExam™, a profit sharing program, allows doctors to access the technology with little financial burden and was launched in 2010 during the recession. To further expand the use of OCT technology, Optovue launched the iStand™, which allows the doctor to scan a patient in any position. Prior to founding Optovue, Jay was a director of advanced development and an OCT program manager at Carl Zeiss Meditec (Humphrey Instruments). He led the OCT development from ground zero in 1993 and delivered all generations of OCT products to the market. Jay has been granted over 30 patents in ophthalmic devices.



WILEY A. CHAMBERS, MD, Deputy Director, Division of Transplant and Ophthalmology Products, Center for Drug

Evaluation and Research, Food and Drug Administration (FDA), is currently a Clinical Professor of Ophthalmology and Adjunct Assistant Professor of Computer Medicine at The George Washington University. He joined the FDA in 1987, as a primary reviewer for ophthalmic drug products and in 1990 became a Supervisory Medical Officer for Ophthalmologic Drug Products. In this capacity, Dr. Chambers has supervisory responsibility for the clinical review of ophthalmologic drug products and ophthalmic therapeutic biologic products submitted to the FDA for study and potential approval. Additionally, Dr. Chambers is the recipient of numerous Public Health Service, FDA and Center for Drug Evaluation and Research awards for his work with the FDA. After receiving an undergraduate degree from Colgate University, Dr. Chambers completed medical school and a residency in Ophthalmology at The George Washington University School of Medicine and Health Sciences in Washington, DC.



GEORGE A. CIOFFI, MD, Chairman, Devers Eye Institute, holds the R.G. Chenoweth Endowed Chair of Ophthalmology

at Devers Eye Institute in Portland, is the Chief Medical Officer and Senior Vice President at Legacy Health, and is a Professor of Ophthalmology at Oregon Health & Science University. He recently has been appointed chairman of the Department of Ophthalmology at Columbia University College of Physicians & Surgeons beginning March, 2012. Dr. Cioffi is an internationally recognized glaucoma researcher and clinician. He joined Devers Eye Institute in Portland,

OR in 1991 as a fellow and was responsible for building the institute's research department. His research investigates how circulatory changes in the optic nerve may lead to glaucoma and best practices in glaucoma surgery. He has been continuously funded for 18 years by the NIH and has more than 200 publications. He is current editor in chief of the *Journal of Glaucoma* and chairman of the Scientific Advisory Committee for the Glaucoma Research Foundation. As Chief Medical Officer at Legacy Health since 2006, Dr. Cioffi oversees patient safety and quality, graduate and continuing education, and medical staff and research. He helped lead Legacy Health's "Big Aims" initiative that succeeded in significantly reducing hospital-associated infections and inpatient mortality to best in class rates. Dr. Cioffi received his undergraduate degree (Magna Cum Laude & Phi Beta Kappa) from the University of Vermont, and his medical degree (cum laude) from the University of South Carolina. He completed his residency at the University of Maryland, where he was chief resident. Since 2002, he has been listed among US News' Best Doctors. Dr. Cioffi has received numerous honors in his career, including the Clinician-Scientist Award from the American Glaucoma Society, the Senior Achievement Award from the American Academy of Ophthalmology, and the 2010 Shaffer-Hetherington-Hoskins award from the Glaucoma Research Foundation in San Francisco.



MALVINA B. EYDELMAN, MD, Division Director, Division of Ophthalmic, Neurological & Ear

Food and Drug Administration (FDA) received her B.S. in Electrical Engineering, with a specialization in biomedical engineering, from Cooper Union in 1987. She received her M.D. degree from Harvard Medical School

and a Doctorate in Health Sciences and Technology from Massachusetts Institute of Technology (M.I.T.) in 1991. A board-certified ophthalmologist, Dr. Eydelman completed an internship in internal medicine at Winthrop University Hospital and residency in Ophthalmology at Long Island Jewish Hospital. In 1995, Dr. Eydelman joined FDA. For the last 16 years, as an Expert Medical Officer, Senior Medical Advisor and Director of the FDA's Division of Ophthalmic, Neurological and Ear, Nose and Throat Devices (DONED), Dr. Eydelman has been involved in all aspects of assuring safety and effectiveness of ophthalmic medical devices. She also has been actively involved in standardization of ophthalmic devices as the US Expert Delegate to the International Standards Organization and FDA's Liaison to the American National Standards Institute's Committee for Ophthalmic Devices. Dr. Eydelman's broad ophthalmic interests have resulted in a United States Patent and numerous publications.



H. DUNBAR HOSKINS, JR., MD, Former Executive Vice President, American Academy of Ophthalmology, a position he

assumed January 1, 1993, after a distinguished career in private practice. Dr. Hoskins is an internationally recognized glaucoma specialist, having authored or co-authored more than 70 publications and presented more than 300 invited lectures throughout the world. He received an Academy Honor Award in 1979 and a Senior Honor Award in 1989 and Distinguished Service Award in 1999. He is also a member of the Alpha Omega Alpha Medical Society, the Sigma Zeta Honor Society, and was listed in the March 1991 issue of *Good Housekeeping* as one of "The 400 Best Doctors in America," as well as being repeatedly listed in the "Best Doctors in

America.” He has held numerous other positions in ophthalmology, medicine and business. Among the highlights: Chairman of St. Mary’s Hospital and Medical Center in San Francisco, Chairman of Mercy Services Corporation, founder and Chairman of Medem Corporation, Founding Director of the American Glaucoma Society, founder and Director of the Glaucoma Research Foundation and Secretary-Treasurer of the Pan American Association of Ophthalmology, and Chairman of the Advisory Committee to the International Council of Ophthalmology. He is a Clinical Professor of Ophthalmology at the University of California San Francisco School of Medicine. Born in Virginia, Dr. Hoskins, the son of an ophthalmologist, received his medical degree at the Medical College of Virginia where he did his internship and residency. He was certified by the American Board of Ophthalmology in 1970 and did his Glaucoma Fellowship at the University of California San Francisco Medical Center. He served as Chief of Ophthalmology at the Naval Hospital in Rhode Island in 1968.



JAMES MAZZO, President and CEO, Abbott Medical Optics assumed the position of president following the company’s

February 2009 acquisition by Abbott [NYSE: ABT], a global, broad-based healthcare company with more than \$30 billion in annual sales. Previously, he was chairman and CEO of Advanced Medical Optics, Inc., a position he assumed following the company’s 2002 spin-off from Allergan, Inc. Abbott Medical Optics Inc. (AMO), is the global leader in advanced refractive technologies for eye care professionals and patients. Headquartered in Santa Ana, California, AMO offers market-leading technologies and services designed to address vision

disorders at all stages of life. While CEO of Advanced Medical Optics, Mr. Mazzo grew the company’s sales from \$538 million in 2002 to more than \$1 billion in 2008 and increased the market cap from approximately \$429 million to approximately \$1.5 billion. During this time, he also engineered several strategic acquisitions worth more than \$3 billion, staking the company to clear leadership positions in the cataract and eye care markets and the global No. 1 position in refractive surgery. Prior to leading AMO, Mr. Mazzo progressed throughout a 22-year career at Allergan, Inc., where he held a variety of senior executive-level positions. He spent approximately 12 years working outside the United States, as president of Allergan’s Europe/Africa/Middle East region, vice president and managing director (Italy), and director of marketing (Canada). Mr. Mazzo is a strong believer in education and serves on the University of California at Irvine (UCI) Dean’s Board of Directors’ Executive Committee, UCI Dean’s Board of Business and Engineering and is chairman of the UCI Foundation. He is also a trustee for Chapman University and the University of San Diego. Additionally, he is a member of the International Intraocular Implant Club (IIIC) and serves as board chairman of AdvaMed.



MARTIN B. WAX, MD, Chief Medical Officer and Executive Vice President, Research and Development,

PanOptica, Inc., was Vice President of R&D and Head of Ophthalmology Discovery Research and Preclinical Sciences at Alcon Laboratories in Ft. Worth, Texas from 2003-2008. PanOptica is a privately owned, venture-backed ophthalmic biopharmaceutical company dedicated to the development of novel therapeutics for eye disease. Dr. Wax

is currently a Clinical Professor of Ophthalmology and Visual Sciences at the University of Texas Southwestern Medical School in Dallas, Texas. He received his medical degree from the University of Southern California in Los Angeles. He completed his residency in Ophthalmology at Wills Eye Hospital in Pennsylvania, and was a postdoctoral fellow first in Neuropharmacology and then in Glaucoma at the University of Pennsylvania School of Medicine in Philadelphia. Prior to entering industry as the head of Ophthalmology Research at Pharmacia Corporation in 2002, he held the distinguished Research to Prevent Blindness Chair as a Professor of Ophthalmology at Washington University School of Medicine in St. Louis, MO. He has coauthored more than 200 publications including peer-reviewed articles, abstracts and chapters in books and is an internationally recognized scientific expert in the field of glaucoma. His research has focused on the cell biology of aqueous humor formation and the role of the immune system in glaucomatous optic neuropathy. Dr. Wax was the recipient of the 1991 Robert E. McCormick Scholarship and the 1995 Lew R. Wasserman Merit Award for his contributions to basic eye research, the 1999 Rudin Prize from the NY Academy of Medicine, the 2001 Senior Investigator Award from Research to Prevent Blindness, the 2003 Clinician-Scientist Award from the American Glaucoma Society and the 2010 Barany Prize in Ocular Pharmacology from ISER. He is a member of the American Academy of Ophthalmology, the Association for Research in Vision and Ophthalmology, the Society for Neuroscience, the International Society for Eye Research, and the American Glaucoma Society. He currently serves on several national and international Scientific Advisory Committees, Editorial Boards, and corporate Boards.



ANAND MEHRA, MD, Partner, Sofinnova Ventures, joined Sofinnova Ventures in 2007 to focus on biopharmaceutical investing. Anand's diverse background equips him to work with entrepreneurs on scientific, clinical, and strategic levels. Currently, he is a director of Marinus and Nextwave Pharmaceuticals, and led the firm's investments in Vicept (Acquired: Allergan) and Aerie. Anand also played an important role in the firm's investments in Hyperion, Preglem (Acquired: Gedeon Richter), and Amarin (NASDAQ: AMRN).

Prior to joining Sofinnova Ventures, Anand worked in JP Morgan's private equity and venture capital group, where he was heavily involved in new investments, management of their public portfolio, and the firm's spin-out from the bank. Before joining the venture community, Anand was a consultant in McKinsey & Company's pharmaceutical practice, advising pharma and biotech on key strategic issues, and an NIH-funded Fellow focused on reperfusion injury in stroke.

Anand received his M.D. from Columbia Medical School and graduated Phi Beta Kappa from the University of Virginia.



STUART B. ABELSON, MBA, President and Chief Executive Officer, ORA, Inc., a leading independent ophthalmic drug and device development firm, has been a Director since 1995 and served as the company's Chairman from 1997 until his appointment as President in 2007. Prior to joining Ora in an operating capacity, Mr. Abelson served in various positions including most recently Director of Technical Business Development at Amphenol, one of the largest manufacturers of interconnect products in the world. From 1999 through 2005, he served as General Manager of Amphenol's fiber optic product division. Mr. Abelson graduated Phi Beta Kappa and Magna Cum Laude with a B.S. degree in neuroscience from Bates College where he was a Charles A. Dana Scholar. He holds an MBA from Northwestern University's Kellogg School of Management. Mr. Abelson is a Trustee of Massachusetts Eye & Ear Infirmary, Bates College and the Chicago Zoological Society, and he serves on the Alumni Council of the Kellogg School of Management.



ANTHONY P. ADAMIS, MD, Vice President and Global Head of Ophthalmology, Genentech, Inc., a member of the Roche Group, co-founded Eyetech (2000) and Jerini Ophthalmic (2007). At Eyetech, Dr. Adamis helped lead the team that obtained FDA approval for the first anti-VEGF drug in ophthalmology. From 1991 to 2002, Dr. Adamis was on the full time faculty of the Harvard Medical School and was co-director of the Ocular Angiogenesis Laboratory at the Massachusetts Eye and Ear Infirmary. His research is focused on AMD and diabetic

retinopathy, as well as ocular drug delivery. Dr. Adamis is best known for his co-discovery of the role of VEGF in ocular disease. He received his M.D. with Honors from the University of Chicago, and completed his ophthalmology residency at the University of Michigan and fellowship in corneal disease at the Massachusetts Eye and Ear Infirmary. His research training in vascular biology was with Dr. Judah Folkman at the Children's Hospital of Boston.



KFIR AZOULAY, Vice President and General Manager of the Ophthalmology Business Unit, Lumenis, Ltd., brings over 13 years of experience in the medical device industry in general, and in the field of ophthalmology in particular. During his decade-

long tenure with Lumenis, the world's largest laser- and light-based medical device company, he has held various marketing, product management and commercial operations roles in different locations around the world. Mr. Azoulay is fluent in 4 languages and resides in Amsterdam, the Netherlands. He studied Cognitive Sciences; and he also completed the Ophthalmology Clinical and Science Program at Columbia University in NY.



EUGENE DE JUAN, JR., MD, Founder and Vice-Chairman, ForSight Labs is a renowned retinal surgeon, inventor, and entrepreneur, actively participating as inventor and advisor in early-stage ophthalmic device opportunities. Dr. de Juan,

Jr., splits his time between ForSight Labs and UCSF and holds the "Jean Kelly Stock Distinguished Chair" in Ophthalmology and continues to see patients, operate and teach at UCSF. Dr. de Juan, Jr., has participated in the development of a number of ophthalmology's most exciting new technologies with over 100 products and founding a number of venture funded companies, including Second Sight, InnoRx (bought by Surmodics in 2005), and NeoVista, Inc., in addition to ForSight Labs' first company Transcend Medical, founded in 2005.

Prior to moving to San Francisco, Dr. de Juan, Jr., was a professor of ophthalmology at the University of Southern California and Chief Executive Officer of the Doheny Retina Institute, focusing on innovative techniques for treating blinding retinal disorders through retinal transplantation, macular translocation, robotic surgery, retinal implants and other new procedures, medicines and instruments.

Prior to these positions, Dr. de Juan, Jr., served at the Wilmer Eye Institute at Johns Hopkins University School of Medicine, where he was co-director of Vitreoretinal Service, director of the Microsurgery Advanced Design Laboratory (MADLAB) and Joseph E. Green Professor of Ophthalmology. From 1983 to 1992 he was a member of the medical staff of the Duke University Eye Center, holding

joint teaching appointments with the departments of ophthalmology and cell biology.

Dr. de Juan, Jr., completed his medical degree and internship training at the University of South Alabama College of Medicine. He served an internship at University of South Alabama Medical Center followed by a residency at the Wilmer Ophthalmological Institute in Baltimore, Maryland, and a fellowship in vitreoretinal surgery at Duke University. He holds patents on over 40 medical devices and is responsible for more than 200 academic publications.



JOHN W. GRUNDEN, PharmD, Regional Director of Medical Affairs, Merck & Co., Inc., is responsible for U.S. and global glaucoma medical activities, including the conduct of clinical trials, investigator-initiated research grants, strategic planning, and

interactions with global regulatory agencies. Prior to his appointment at Merck in 2011, he worked in global medical affairs at Pfizer and at Pharmacia where he supported the Ophthalmology Franchise from the time of Xalatan's launch in 1996. He has also held numerous academic appointments. Dr. Grunden received his Doctor of Pharmacy degree from the University of Utah after obtaining a Bachelor of Pharmacy degree from Washington State University. Following a residency in Clinical Pharmacy Practice, he completed a specialized residency at the University Hospital and Clinics in Salt Lake City, Utah. Dr. Grunden was elected to the Glaucoma Research Foundation Board of Directors in January 2009.



WENDE HUTTON, General Partner, Canaan Partners, is a seasoned healthcare investor, passionate about identifying, investing in and building companies that are revolutionizing the practice of medicine. She joined Canaan in 2004,

bringing diverse expertise from across the entire medical spectrum. Over the last 18 years, Wende has facilitated the market entrance of over 11 novel and lifesaving medical devices, new drugs and diagnostics. Her track record is a testament to her leadership and includes the initial public offerings of five companies, of which two were later acquired, and the acquisition of four more by medical companies including the recent acquisition of BiPar Sciences, a leader in the development of a potential new class of tumor-selective drugs designed to meet the unmet needs of cancer patients. Wende began her venture career at Mayfield Fund in 1993, where she was a General Partner in the life sciences group until 2001. During her tenure at Mayfield, Wende incubated Heartstream Inc. (HPQ) and Northstar Neuroscience Inc. (NSTR). Most recently, she was a General Partner

at Spring Ridge Ventures, a healthcare-focused seed fund. Earlier in her career, Wende held senior operational management positions at GenPharm International and Nellcor in business development and marketing.

Wende sits on the boards of Aldea Pharmaceuticals, Altheos, Inc., Calibra Medical, Dermira, Inc., ReVision Optics, Inc., Theraclone Sciences and Transcend Medical, Inc. Her previous board seats include Alsius (ALUS), Apieron, Inc. (Acquired by Aerocrine), BiPar Sciences (acquired by Sanofi), Heartstream, Inc. (acquired by Hewlett Packard), Micro Therapeutics, Inc. (acquired by ev3, Inc.), Northstar Neuroscience (NSTR), Orquest, Inc. (acquired by Johnson & Johnson), and SenoRx, Inc. (acquired by C. R. Bard). Wende holds a BA in human biology from Stanford University and an MBA from Harvard Business School, where she was a Baker Scholar.



WILLIAM J. LINK, PhD, Managing Director, Versant Ventures, specializes in early-stage investing in medical devices at Versant. Prior to co-founding Versant Ventures, Bill was a general partner at Brentwood Venture Capital. He has a

proven record of building and operating large, successful medical product companies. With extensive knowledge of medical devices, particularly in ophthalmology, his operating experience spans more than 23 years in general management in the healthcare industry.

Perhaps Bill's greatest operational success was as founder, chairman and CEO of Chiron Vision, a subsidiary of Chiron Corporation specializing in ophthalmic surgical products, which was sold to Bausch + Lomb in 1997. Prior to Chiron Vision, Bill founded and served as President of American Medical Optics (AMO), a division of American Hospital Supply Corporation, which was sold to Allergan in 1986. Later Bill served on the Board of AMO's successor company, Advanced Medical Optics. AMO was acquired by Abbott in 2009.

While at Brentwood, Bill invested in a number of early-stage companies, including eyeonics (sold), Genyx (sold), IntraLase (sold), Intra Therapeutics (sold), and OraMetrix (private). His Versant investments include the following private companies: AcuFocus, Cameron Health, ForSight, Glaukos, Inogen, LenSx (sold), NeoVista, Neurotech Pharmaceuticals, Rox Medical, Second Sight and Wavetec. Bill also serves as a Director of Edwards Lifesciences.

Before entering the healthcare industry, Bill was an Assistant Professor in the Department of Surgery at the Indiana University School of Medicine. Bill earned his Bachelor's, Master's, and Doctorate degrees in Mechanical Engineering from Purdue University.



DAVID MORDAUNT, PhD, Vice President, Research and Development/Surgical, Bausch + Lomb, has an extensive background in the medical device industry as an innovator, senior executive and business leader. He has built several businesses and is currently the Vice President of R&D for Bausch + Lomb's Surgical business. Prior to joining Bausch + Lomb, he founded and was CEO of two companies: OptiMedica, the leading company in ophthalmic scanning lasers within the eye; and Precision Light, the leader in 4D imaging and outcome simulation in plastic surgery. David has also assisted physicians in developing innovative technologies and clinical applications for Ophthalmology, Urology, GYN and Dermatology. David is responsible for the development of over 50 new medical devices and establishing 6 new clinical applications with leading physicians, which have become the standard of care in their respective fields, resulting in many patents and peer-review papers, and several book chapters. David has a Ph.D. in Chemistry and a Bachelors of Science in Chemical Physics from the University of Bristol. He has also been awarded several academic fellowships and awards for innovation.



IOK-HOU PANG, PhD, FARVO, Head Glaucoma Research, Alcon Laboratories, Inc., has been involved in drug discovery for glaucoma therapy for more than 20 years. He has identified and characterized novel compounds for glaucoma treatment, successfully advanced a series of compounds to clinical evaluations. He has also contributed to the understanding of mechanisms and signaling pathways involved in the regulation of aqueous hydrodynamics, pathological changes in the trabecular meshwork, as well as glaucoma optic neuropathy and retinopathy. He is an inventor in numerous US and international patents, published more than 80 research manuscripts and book chapters, and edited a book.




MIKE PATELLA, Vice President, Professional Affairs, Carl Zeiss Meditec, Inc., has devoted most of his working life to the development of automated diagnostic devices for ophthalmology. He holds degrees in physics, meteorology, and optometry, and began his career as an aerospace engineer working on manned spaceflight. Dr. Patella led the development of the Humphrey perimeter and has co-authored two books and numerous scientific papers on automated perimetry. He also has been directly involved in the development of Optical Coherence Tomography for over 15 years. Dr. Patella continues to lecture globally and to develop and maintain collaborations with colleagues throughout the world.



JANE E. RADY, Divisional Vice President, Business Development, Abbott Medical Optics (AMO) was a corporate officer of Advanced Medical Optics (NYSE symbol EYE) from 2002 to 2009 prior to AMO's acquisition by Abbott in 2009. Prior to joining AMO, Ms. Rady was a director and the CEO of Integrated Genomics, Inc. and was a consultant to Integrated Genomics and several other companies in 2001. From 1984 to 2000, she was employed by G.D. Searle & Co. in various capacities including president and general manager of Searle's international joint venture, Lorex Pharmaceuticals Ltd., vice president of corporate licensing & business development, and vice president of strategic planning. Prior to that, she headed venture investing activities in Monsanto focusing on emerging technologies and businesses in biotechnology. Ms. Rady began her career in Chicago with Abbott Laboratories. Jane received her Bachelor and Master of Science from the University of Illinois in molecular biology/microbiology and her MBA from Northwestern's Kellogg School of Management. Academic awards include Phi Beta Kappa, Phi Kappa Phi and Beta Gamma Sigma. She serves as a board member on the University of California Irvine's Biomedical Engineering Corporate Advisory Board, as a member of the board of directors for the Medical Device Manufacturer's Association, and as an advisor to the southern California chapter of Healthcare Businesswomen's Association.



RHETT M. SCHIFFMAN, MD, MS, MHSA, VP and Therapeutic Area Head, Ophthalmology, Allergan, Inc., joined Allergan in 2001, and had responsibility for the approval of numerous ophthalmic medications including RESTASIS™, ELESTAT™, ZYMAR™, ZYMAXID™, ACULAR LS™, ACUVAIL™, COMBIGAN™ and LUMIGAN 0.01%™. Dr. Schiffman holds a BS in Bioengineering from Columbia University, School of Engineering and Applied Sciences, an MD from the University of Juarez, Mexico, and Master's Degrees in Clinical Research Design and Statistical Analysis and in Health Services Administration from the University of Michigan. He is Board Certified, having completed residencies in Internal Medicine and in Ophthalmology at Henry Ford Hospital, as well as a Fellowship in Uveitis and Ocular Immunology at the National Eye Institute of the National Institutes of Health. He continues to see patients and teach residents at the University of California at Irvine where he is Associate Clinical Professor of Ophthalmology. Dr. Schiffman joined the Glaucoma Research Foundation Board of Directors in 2010.



Andrew G. Iwach, MD, Board Chair

Thomas M. Brunner, President & CEO

H. Allen Bouch, Vice Chair

Michael L. Penn, Sr., Secretary

Frederick H. Brinkmann, Treasurer

J. Bronwyn Bateman, MD

C. Seth Cunningham

Timothy J. Dwyer

Adrienne Graves, PhD

John W. Grunden, PharmD

John Hetherington, MD

H. Dunbar Hoskins, Jr., MD

Linda Linck

Deirdre Porter

Rhett M. Schiffman, MD, MS, MHSA

Kuldev Singh, MD, MPH

Dennis E. Singleton

Robert L. Stamper, MD

Bill Stewart

Art Takahara

George E. Thomas

Martin B. Wax, MD

Mona Zander



Save the Date for Glaucoma 360° 2013

Three events. One mission.

The first 3-day event uniting research, industry & philanthropy to find a cure for the world's leading cause of preventable blindness.

January 31 - February 2, 2013

The Palace Hotel | San Francisco, CA

Glaucoma.
We've got it surrounded.

**NEW
HORIZONS
FORUM**

**CATALYST
FOR A CURE
BENEFIT**

**GLAUCOMA
SYMPOSIUM
CME**

Please direct early inquiries to
events@glaucoma.org

GLAUCOMA
RESEARCH FOUNDATION